What are Ligand Pharmaceuticals's profit margins?

Gross margin is 91.9% and operating margin is 34.5%, with a 55.9% net margin.

Where does Ligand Pharmaceuticals's income statement data come from?

Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Ligand Pharmaceuticals LGND Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$268.09M+60.4%	$167.13M+27.3%	$131.31M-33.1%	$196.25M-18.8%
Research and development	$81.18M+279%	$21.43M-12.7%	$24.54M-32.0%	$36.08M+12.4%
General and administrative	$92.45M+17.5%	$78.65M+49.0%	$52.79M-24.7%	$70.06M+49.7%
Total costs & expenses	$227.09M+19.7%	$189.74M+56.2%	$121.49M-37.1%	$193.21M+40.3%
Operating income	$41M+281%	-$22.61M—	——	——
Operating margin	15.3%+28.8pp	-13.5%—	——	——
Interest expense	$4.72M+55.5%	$3.03M+362%	$656K-63.5%	$1.8M-90.8%
Interest income	$13.66M+69.6%	$8.06M+4.5%	$7.71M+277%	$2.05M+131%
Other income (expense), net	$117.96M—	——	$51.72M+56.8%	$32.97M+204%
Gain (loss) on disposal of assets	$0—	$0—	——	-$14.79M-1,478,500%
Income before income taxes	$158.96M—	——	$63.66M+76.8%	$36.01M-50.1%
Income tax expense	$34.51M—	——	——	$41.23M—
Net income	$124.45M+3,187%	-$4.03M-108%	$52.15M+256%	-$33.36M-158%
Net margin	46.4%+48.8pp	-2.4%-42.1pp	39.7%+56.7pp	-17%-40.7pp
Diluted earnings per share	$5.89+3,045%	-$0.20-107%	$2.90+261%	-$1.80-152%
Basic earnings per share	$6.36+4,992%	-$0.13-104%	$3.05+269%	-$1.80-150%
Weighted-average shares, diluted	80M+9.9%	72.9M+2.8%	70.8M+4.4%	67.9M-0.6%
Weighted-average shares, basic	77.4M+6.9%	72.5M+5.0%	69M+2.3%	67.5M+1.4%
Amortization of acquired technology	$32.71M-0.8%	$32.96M-2.1%	$33.65M-1.7%	$34.24M-3.3%
Purchased power and fuel	$14.55M+31.4%	$11.07M+5.3%	$10.51M-80.1%	$52.83M-15.0%
Derivative, Gain (Loss) on Derivative, Net	$0+100%	-$15.06M—	——	$0—
Loss from change in fair value of equity-method investments and other investments	$90.67M—	——	$0—	——
Other income, net (Note 6)	——	-$51.89M—	——	——
Revenue From Contract With Customer Excluding Assessed Tax	$268.09M+60.4%	$167.13M+27.3%	$131.31M-33.1%	$196.25M-18.8%
EBIT	$41M+281%	-$22.61M-169%	$32.53M-31.5%	$47.52M-54.2%
EBITDA	$74.78M+492%	$12.63M-81.7%	$69.05M-30.3%	$99.05M-36.1%
EBITDA	$74.78M+492%	$12.63M-81.7%	$69.05M-30.3%	$99.05M-36.1%
EBITDA margin	27.9%+20.3pp	7.6%-45.0pp	52.6%+2.1pp	50.5%-13.7pp
EBIT	$41M+281%	-$22.61M-169%	$32.53M-31.5%	$47.52M-54.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Ligand Pharmaceuticals's profit margins?: Gross margin is 91.9% and operating margin is 34.5%, with a 55.9% net margin.
Where does Ligand Pharmaceuticals's income statement data come from?: Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.